Study: Idarucizumab Safely Reverses Anticoagulant Effect of Dabigatran
Idarucizumab (Praxbind), the first reversal agent for one of the non-vitamin K oral anticoagulants, acts quickly and safely, according to a new study. More than 500 patients who were anticoagulated with dabigatran required reversal because of uncontrolled bleeding or need for an urgent procedure. Patients received 5 g of IV idarucizumab as two infusions 15 minutes apart. The maximum percentage reversal of dabigatran was 100%. In bleeding patients, the median time to cessation of bleeding was 2.5 hours. In the procedure group, 93.4% of patients exhibited normal periprocedural hemostasis at 1.6 hours. Within three months, thrombotic events occurred in 6.3% of the bleeding group and 7.4% of the procedure group. Mortality was about 19% in both groups. The authors concluded that “idarucizumab rapidly, durably, and safely reversed the anticoagulant effect of dabigatran.” (N Engl J Med 2017;377:431-441)
Promising evidence emerges about the efficacy of the first reversal agent for one of the non-vitamin K oral anticoagulants.
Subscribe Now for Access
You have reached your article limit for the month. We hope you found our articles both enjoyable and insightful. For information on new subscriptions, product trials, alternative billing arrangements or group and site discounts please call 800-688-2421. We look forward to having you as a long-term member of the Relias Media community.